Seres Therapeutics (MCRB) Tops Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Seres Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Operational Progress Update
March 16, 2017 7:00 AM EDT- Positive SER-109 Type B FDA meeting -
- Company to initiate new Phase 2 SER-109 clinical trial that, as agreed to by the FDA, may qualify as a Pivotal Study with achievement of a persuasive clinical effect and addressing FDA requirements -
- Continued pipeline progress with both SER-287 and SER-262 Phase 1b studies; Both data read-outs expected in the second half of 2017 -
- Conference call at 8 a.m. ET today -
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics Inc., (NASDAQ:... More
Seres Therapeutics to Initiate New SER-109 Clinical Study
March 16, 2017 7:00 AM EDTPositive SER-109 Type B FDA meeting
Seres and FDA reach agreement on key design elements of a new SER-109 Phase 2 study in patients with multiply recurrent C. difficile infection
New trial may qualify as a Pivotal Study with achievement of a persuasive clinical effect and addressing FDA requirements
Conference call at 8 a.m. ET today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics Inc., (NASDAQ: MCRB), a leading microbiome therapeutics platform company, today announced plans to initiate a new SER-109 Phase 2 clinical... More
